Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields Combined With Chemoradiation in Newly Diagnosed Glioblastoma (Unity)
NCT03705351Phase 1Terminated
- Start
- Dec 2019
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioblastoma (GBM). Primary endpoints: Rate of Treatment-Related Adverse Events Associated With Trimodal Therapy at 15 weeks and Severity of Treatment-Related Adverse Events Associated With Trimodal Therapy at 15 weeks. Started Dec 2019; status: terminated.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03705351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03705351.